Vernalis’ drug discovery platform to be used on an undisclosed oncology target.



Vernalis and Servier entered into a joint, three-year, oncology drug discovery collaboration. Under the terms of the collaboration, which utilizes Vernalis’ drug discovery platform on an undisclosed target, Vernalis will receive an upfront payment and a share in the downstream success of the product.


“The partnership with Vernalis is a major step in our strategy to increase our efforts in the development of novel anti-cancer therapeutic approaches,” remarks Emmanuel Canet, M.D., Ph.D., vp Servier R&D. “This collaboration will expedite the discovery of innovative compounds with potential use in therapeutic indications with high unmet medical need.”








This site uses Akismet to reduce spam. Learn how your comment data is processed.